• Рахимова В.Ш., Ярмухамедова Н.А.
  1 – Ташкентский институт усовершенствования врачей, Республика Узбекистан, г. Ташкент; 2 - Самаркандский государственный медицинский институт, Республика Узбекистан, г. Самарканд

---

Abstract

Эпидемия COVID-19 в основном проявляется диссеминированным повреждением легких с развитием острого респираторного дистресс-синдрома (ОРДС). Но, по-видимому поражение печени при COVID-19 может коррелировать с общей тяжестью заболевания и служить прогностическим фактором. Спектр поражения печени при COVID-19 может варьироваться от прямого заражения SARS-CoV-2, косвенного поражения системным воспалением, а также гипоксических изменений.

Keywords

COVID-19, поражение печени, печеночные ферменты, цитокиновый шторм

Literature

1.    Alqahtani SA, Schattenberg JM. Liver injury in COVID- 19: the current evidence. United European Gastroenterol J. 2020;8:509–519.

2.    Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;[Epub ahead of print]

3.    Chai X, Hu L, Zhang Y, et al Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection [PREPRINT]. bioRxiv. 2020

4.    Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver damage. Clin Gastroenterol Hepatol. 2020;18:1561–1566.

5.    Gu, Y. et al. Interaction network of SARS-CoV-2 with host receptome through spike protein. Preprint at https://doi.org/10.1101/2020.09.09.287508 (2020).

6.    Guan W-J., Ni Z-Y., Hu Y. et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382:1708-20. doi: 10.1056/NEJMoa2002032.)

7.    Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). CAS Article Google Scholar

8.    Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271--280.e8.

9.    Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 e278 (2020). Google Scholar

10. Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359 (2020).

11. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).

12. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).

13. Moher D, Liberati A, Tetzlaff J, Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PRISMA Group. PLoS Med. 2009;6:0.

14. Pan, L. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am. J. Gastroenterol. 115, 766–773 (2020).

15. Phipps MM, Barraza LH, LaSota ED, et al Acute liver injury in COVID‐19: Prevalence and association with clinical outcomes in a large US cohort.. Hepatology. 2020;[Epub ahead of print]

16. Qi X, Liu C, Jiang Z, et al. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury. J Hepatol. 2020;73:455–458.

17. Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. Gastroenterology. 2020;[Epub ahead of print]

18. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e286 (2020).

19. Wan, Y. et al. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. Lancet Gastroenterol. Hepatol. 5, 534–535 (2020).

20. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).

21. Wang, Q. et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil. Med. Res. 7, 28 (2020). PubMed. PubMed Central. Google Scholar

22. Weber S, Mayerle J, Irlbeck M, Gerbes AL. Gut. Severe liver failure during SARS-CoV-2 infection. 2020;69:1365–1367.

23. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260 (2020). Google Scholar

24. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020;40:1321–1326.

25. Yang, W. et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J. Infect. 80, 388–393 (2020).

26. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;[Epub ahead of print].

27. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).